A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program ...

Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.

New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.

Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV ...

The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up ...

Five years after the start of the COVID-19 pandemic, U.S. federal and state health agencies are threatening to abandon research in areas that were critical to ending the global crisis: vaccines and ...

After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley ...

CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave ...

Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths came ...